Epic Test Code LAB163 Varicella-Zoster Virus (VZV) Antibody, IgM, Serum
Additional Codes
MML Code: VZM
LIS Code: HZA
NY State Approved
YesPerforming Laboratory
Mayo Clinic Laboratories in RochesterReporting Name
Varicella-Zoster Ab, IgM, SMethod Name
Immunofluorescence Assay (IFA)
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Serum | Refrigerated (preferred) | 14 days | |
Frozen | 14 days |
Specimen Required
Collection Container/Tube:
Preferred: Serum gel
Acceptable: Red top
Submission Container/Tube: Plastic vial
Specimen Volume: 0.5 mL
Collection Instructions: Centrifuge and aliquot serum into a plastic vial.
Specimen Type
SerumSpecimen Minimum Volume
0.2 mL
Reference Values
Negative
Reference values apply to all ages.
Report Available
Same day/1 to 3 daysDay(s) Performed
Monday through Sunday
CPT Code Information
86787
Reject Due To
Gross hemolysis | Reject |
Gross lipemia | Reject |
Heat-inactivated specimen | Reject |
Useful For
Diagnosing acute-phase infection with varicella-zoster virus
Clinical Information
Varicella-zoster virus (VZV), a herpes virus, causes 2 distinct exanthematous (rash-associated) diseases: chickenpox (varicella) and herpes zoster (shingles). Chickenpox is a highly contagious, though typically benign, disease, usually contracted during childhood. Chickenpox is characterized by a dermal vesiculopustular rash that develops in successive crops approximately 10 to 21 days following exposure.(1) Although primary infection with VZV results in immunity and protection from subsequent infection, VZV remains latent within sensory dorsal root ganglia and upon reactivation, manifests as herpes zoster or shingles. During reactivation, the virus migrates along neural pathways to the skin, producing a unilateral rash, usually limited to a single dermatome. Shingles is an extremely painful condition typically occurring in older nonimmune adults or those with waning immunity to VZV and in patients with impaired cellular immunity.(2)
Several populations are at risk of suffering unusually severe reactions to VZV infections. The infection in pregnant women may spread through the placenta to the fetus causing congenital disease in the infant. Immunocompromised patients in hospitals may contract severe nosocomial infections from others who have active VZV infections and are at risk for developing severe VZV-related complications, which include cutaneous disseminated disease and visceral organ involvement.(2,3) Therefore, serologic screening of direct healthcare providers (physicians, allied healthcare personnel) and individuals in high-risk groups is necessary to avoid uncontrolled spread of infection.
While the clinical presentation of VZV infection is generally characteristic, serologic evaluation of patients with atypical and systemic infections is often required. For example, it is extremely important to serologically evaluate patients for the early detection of VZV infections in hospital settings. Nosocomial spread of VZV infection can be life-threatening to immunocompromised patients susceptible to infection.
Interpretation
A positive IgM result indicates a recent infection with varicella-zoster virus (VZV).
A negative result does not rule out the diagnosis of VZV infection. The specimen may have been drawn before the appearance of detectable antibodies. Negative results in suspected early VZV infection should be followed by testing a new specimen in 2 to 3 weeks.
Cautions
The performance characteristics with individuals vaccinated with varicella-zoster virus (OKA strain) have not been established.
The test must be performed on serum. The use of whole blood, plasma, or cord blood has not been established.
Positive results from cord blood or neonates should be interpreted with caution.
Results from immunocompromised patients should be interpreted with caution.
Specimen Retention Time
14 daysForms
If not ordering electronically, complete, print, and send Infectious Disease Serology Test Request (T916) with the specimen.